NCT05864924View on ClinicalTrials.gov

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

April 26, 2024

Study Completion Date

April 26, 2024

Conditions
EBV-positive Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

Cohort A: 3.0x10^6 CAR-T cells/kg

Intravenous infusion

BIOLOGICAL

Cohort B: 9.0x10^6CAR-T cells/kg

Intravenous infusion

BIOLOGICAL

Cohort C:1.5x10^7 CAR-T cells /kg

Intravenous infusion

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

BioSyngen Pte Ltd

INDUSTRY

NCT05864924 - A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter